Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 한상웅 | - |
dc.date.accessioned | 2018-02-26T01:09:21Z | - |
dc.date.available | 2018-02-26T01:09:21Z | - |
dc.date.issued | 2016-03 | - |
dc.identifier.citation | KOREAN JOURNAL OF INTERNAL MEDICINE, v. 31, NO 2, Page. 335-343 | en_US |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | http://kjim.org/journal/view.php?doi=10.3904/kjim.2014.266 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/40547 | - |
dc.description.abstract | Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in patients with favorable prognostic features. In this study, we aimed to investigate the antiproteinuric effect and tolerability of low-dose valsartan (an angiotensin II receptor blocker) therapy in normotensive IgAN patients with minimal proteinuria of less than 0.5 to 1.0 g/day. Methods: Normotensive IgAN patients, who had persistent proteinuria with a spot urine protein-to-creatinine ratio of 0.3 to 1.0 mg/mg creatinine, were recruited from five hospitals and randomly assigned to either 40 mg of valsartan as the low-dose group or 80 mg of valsartan as the regular-dose group. Clinical and laboratory data were collected at baseline, and at 4, 8, 12, and 24 weeks after valsartan therapy. Results: Forty-three patients (low-dose group, n = 23; regular-dose group, n = 20) were enrolled in the study. Proteinuria decreased significantly not only in the regular-dose group but also in the low-dose group. The change in urine protein-to-creatinine ratio at week 24 was -41.3% +/- 26.1% (p < 0.001) in the regular- dose group and -21.1% +/- 45.1% (p = 0.005) in the low-dose group. In the low-dose group, blood pressure was constant throughout the study period, and there was no symptomatic hypotension. In the regular-dose group, blood pressure decreased at weeks 8 and 12. No significant change in glomerular filtration rate, serum creatinine level, or serum potassium level was observed during the study period. Conclusions: Our results suggest that low-dose valsartan can significantly reduce proteinuria without causing any intolerability in normotensive IgAN patients with minimal proteinuria. | en_US |
dc.description.sponsorship | This work was supported by BK-21, Konkuk University. | en_US |
dc.language.iso | en | en_US |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | en_US |
dc.subject | Angiotensin receptor antagonists | en_US |
dc.subject | Glomerulonephritis | en_US |
dc.subject | IGA | en_US |
dc.subject | Proteinuria | en_US |
dc.subject | Safety | en_US |
dc.subject | Treatment outcome | en_US |
dc.title | Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 31 | - |
dc.identifier.doi | 10.3904/kjim.2014.266 | - |
dc.relation.page | 335-343 | - |
dc.relation.journal | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.contributor.googleauthor | Jo, Young-Il | - |
dc.contributor.googleauthor | Na, Ha-Young | - |
dc.contributor.googleauthor | Moon, Ju-Young | - |
dc.contributor.googleauthor | Han, Sang-Woong | - |
dc.contributor.googleauthor | Yang, Dong-Ho | - |
dc.contributor.googleauthor | Lee, Sang-Ho | - |
dc.contributor.googleauthor | Park, Hyeong-Cheon | - |
dc.contributor.googleauthor | Choi, Hoon-Young | - |
dc.contributor.googleauthor | Lim, So-Dug | - |
dc.contributor.googleauthor | Kie, Jeong-Hae | - |
dc.relation.code | 2016007062 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | cardion | - |
dc.identifier.orcid | http://orcid.org/0000-0003-3658-7248 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.